Bacil Pharma Current Share Price | Bacil Pharma Stock Screener
BACPHAR
Pharmaceuticals
Bacil Pharma Current Stock Price Today
Live Share Price BSE
₹21.44
▲
0.78 (3.78%)
As of September 18, 2026, the live Bacil Pharma share price (BSE: BACPHAR) is ₹21.44, up 3.78% from the previous close, with shares trading between ₹20.00 and ₹21.50 in today's trading session, and a 52-week range of ₹11.21–₹59.89.
Browse BACPHAR annual financials to support your investment research.
Use the Bacil Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Bacil Pharma Market Cap
₹27.82 Cr.
BACPHAR P/E Ratio (TTM)
40.13
Bacil Pharma P/B Ratio
1.05
EPS (TTM)
₹1.11
Dividend Yield
-
Debt to Equity
-
BACPHAR 52 Week High
₹59.89
Bacil Pharma 52 Week Low
₹11.21
Operating Margin
-
Profit Margin
-
BACPHAR Revenue (TTM)
-
EBITDA
-
Net Income
₹1.00
Total Assets
₹27.00
Total Equity
₹25.00
Bacil Pharma Current Share Price Chart
Track the current Bacil Pharma share price and stock price with an interactive chart. Analyse BACPHAR price trends, trading volume, historical performance, and volatility across different timeframes — the complete Bacil Pharma stock quote in one place.
Bacil Pharma Company Profile - Fundamental Screener
Screen Bacil Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for BACPHAR shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE711D01018
Bacil Pharma Balance Sheet Screener
Screen BACPHAR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 27 | 26 | 1 | 1 | 1 | 4 | 4 | 5 | 5 | 7 |
| Current Assets | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 3 | 6 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 25 | 25 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 6 |
| Share Capital | 14 | 14 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves & Surplus | 11 | 12 | -5 | -5 | -5 | -5 | -5 | -5 | -4 | 0 |
Bacil Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Bacil Pharma income statement and profit fundamentals.
Analyze BACPHAR quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Bacil Pharma share price evaluation.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | 0 | 1 | 0 | 0 | 0 | -4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 1 | 0 | 0 | 0 | -4 | 0 | 0 | 0 | -4 | 0 | 0 | 0 |
| Tax | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 2 | 0 | 0 | 0 | -4 | 0 | 0 | 0 | -4 | 0 | 0 | 0 |
| EPS | 0.70 | 1.11 | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 | -0.54 | -0.58 | -6.37 | 0.00 | -0.11 | -0.05 |
Bacil Pharma Cash Flow Screener - Liquidity Fundamentals
Screen BACPHAR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1 | 0 | 0 | 0 | -4 | 0 | 0 | 0 | 1 | 0 |
| Investing Activities | -2 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | -1 | 0 |
| Financing Activities | -1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | -2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bacil Pharma Shareholding Pattern Screener
See Bacil Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Bacil Pharma promoter holding and ownership changes for BACPHAR on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Jul | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 0.00% | 0.00% | 0.20% | 0.20% | 0.08% | 0.08% | 0.08% | 42.67% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 98.26% | 95.77% | 75.77% | 77.37% | 79.74% | 80.95% | 80.95% | 53.89% |
| Other Holding | 1.74% | 4.23% | 24.03% | 22.43% | 20.18% | 18.97% | 18.97% | 3.44% |
| Shareholder Count | 7,226 | 7,326 | 7,638 | 7,532 | 7,541 | 7,431 | 7,431 | 6,770 |
Bacil Pharma Share Dividend Screener - Share Yield Analysis
Check Bacil Pharma dividend history with payout and yield data.
View Bacil Pharma dividend details including ex-dates and amounts for BACPHAR stock.
Bacil Pharma Stock Index Membership
See which indices include Bacil Pharma stock.
Check BACPHAR index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Bacil Pharma Market Events Screener - Corporate Actions
Get Bacil Pharma corporate actions including splits, bonuses, and buybacks.
Check Bacil Pharma stock events that may affect BACPHAR share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-23 | 2026-09-23 | Annual General Meeting | NA | 61.50% |
| 2026-08-12 | 2026-08-12 | Quarterly Result Announcement | NA | -18.45% |
| 2026-05-22 | 2026-05-22 | Quarterly Result Announcement | NA | -5.53% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 7.69% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -6.67% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | 15.34% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -0.21% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 0.00% |
| 2025-01-21 | 2025-01-21 | Quarterly Result Announcement | NA | -8.02% |
| 2024-11-14 | 2024-11-14 | Extraordinary General Meeting | NA | 26.52% |
| 2024-10-23 | 2024-10-23 | Quarterly Result Announcement | NA | 10.34% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | 31.36% |
Bacil Pharma Competitors Screener - Peer Comparison
Screen BACPHAR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Bacil Pharma Company Announcements - News Screener
Screen BACPHAR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-08-31 | Reg. 34 (1) Annual Report. | - |
| 2026-08-29 | Notice Of Annual General Meeting To Be Held On 23Rd September 2026 | - |
| 2026-08-29 | Intimation For Book Closure | - |
| 2026-08-29 | Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th August 2026 | - |
| 2026-08-26 | Board Meeting Intimation for Bacil Pharma Limited ("The Company") Will Be Held On 29Th August 2026 | - |
| 2026-08-25 | Appointment Of Director | - |
| 2026-08-25 | Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th August 2026 | - |
| 2026-08-17 | Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 25Th August 2026 | - |
| 2026-08-12 | Un-Audited Financial Results For The Quarter Ended 30Th June 2026 | - |
| 2026-08-12 | Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th August 2026 | - |
| 2026-08-06 | Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 12Th August 2026 | - |
| 2026-07-28 | Announcement Under Regulation 30 LODR | - |
| 2026-07-18 | Attached Resignation Of Directors As Query Raised From BSE | - |
| 2026-07-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-10 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-07-09 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-07-09 | Announcement under Regulation 30 (LODR)-Raising of Funds | - |
| 2026-07-09 | Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-07-07 | Intimation Regarding Approval Of Name For Proposed Wholly-Owned Subsidiary | - |
| 2026-07-03 | Board Meeting Intimation for We Hereby Inform You That A Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Thursday 9Th July 2026 | - |